



Figure 1 From genotype to phenotype.

sense, it would have been very interesting to analyse whether PRS combined with results of SCB and other risk factors⁶ could better define the arrhythmic risk in BrS. In other words, an important study, an important first step that needs further scientific follow-up; an important analysis that, like all significant analyses, gives us some answers but opens up multiple new questions (Figure 1).

Conflicts of interest: none declared.

References

1. Tadros R, Tan HL, for the ESCAPE-NET Investigators, el Mathari S, Kors JA, Postema PG, Lahrouchi N, Beekman L, Radivojkov-Blagojevic M, Amin AS, Meitinger T, Tanck MW, Wilde AA, Bezzina CR. Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores. *Eur Heart J* 2019;**40**:3097–3107.
2. Strauss DG, Vicente J, Johannesen L, Blinova K, Mason JW, Weeke P, Behr ER, Roden DM, Woosley R, Kosova G, Rosenberg MA, Newton-Cheh C. Common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk. *Circulation* 2017;**135**:1300–1310.
3. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med* 2015; **372**:793–795.
4. Bezzina CR, Barc J, Mizusawa Y, Remme CA, Gourraud JB, Simonet F, Verkerk AO, Schwartz PJ, Crotti L, Dagradi F, Guicheney P, Fressart V, Leenhardt A, Antzelevitch C, Bartkowiak S, Borggrefe M, Schimpf R, Schulze-Bahr E, Zumhagen S, Behr ER, Bastiaenen R, Tfelt-Hansen J, Olesen MS, Kääh S, Beckmann BM, Weeke P, Watanabe H, Endo N, Minamino T, Horie M, Ohno S, Hasegawa K, Makita N, Nogami A, Shimizu W, Aiba T, Froguel P, Balkau B, Lantieri O, Torchio M, Wiese C, Weber D, Wolswinkel R, Coronel R, Boukens BJ, Béziau S, Charpentier E, Chatel S, Despres A, Gros F, Kyndt F, Lecointe S, Lindenbaum P, Portero V, Violleau J, Gessler M, Tan HL, Roden DM, Christoffels VM, Le Marec H, Wilde AA, Probst V, Schott JJ, Dina C, Redon R. Common variants at SCN5A–SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. *Nat Genet* 2013;**45**:1044–1049.
5. Dooijes D, Siemelink M, Baas AF. Evaluation of gene panels for inherited cardiac disease—is less more? *Neth Heart J* 2019;**27**:297–298.
6. Sieira J, Conti G, Ciconte G, Chierchia GB, Casado-Arroyo R, Baltogiannis G, Di Giovanni G, Saitoh Y, Juliá J, Mugnai G, La Meir M, Wellens F, Czaplá J, Pappaert G, de Asmundis C, Brugada P. A score model to predict risk of events in patients with Brugada syndrome. *Eur Heart J* 2017;**38**: 1756–1763.

Downloaded from https://academic.oup.com/eurheartj/article-abstract/40/37/3109/5498954 by Ferdinand Postma Library user on 06 November 2019

Corrigendum

doi:10.1093/eurheartj/ehz373
 Online publish-ahead-of-print 27 May 2019

Corrigendum to: May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension [*Eur Heart J* 2019;**40**:2006–2017].

In the original version of this article, a small number of the MMM Investigators were missing or recorded incorrectly, and an author’s affiliation was incorrect. This has now been corrected online and in print.

The authors apologise for the error.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com